Progression pattern and post-progression treatment of furmonertinib (AST2818) in EGFR T790M mutation positive NSCLC patients: A post-hoc analysis from a multicenter, single-arm study.

Xingsheng Hu,Shucai Zhang,Dongqing Lv,Lin Wu,Qitao Yu,Yiping Zhang,Li Liu,Xiang Wang,Ying Cheng,Zhiyong Ma,Hongrui Niu,Dong Wang,Jifeng Feng,Cheng Huang,Chunling Liu,Hui Zhao,Jingzhang Li,Xiaodong Zhang,Yong Jiang,Yuankai Shi

Progression pattern and post-progression treatment of furmonertinib (AST2818) in EGFR T790M mutation positive NSCLC patients: A post-hoc analysis from a multicenter, single-arm study.

2021

e21071Background: Furmonertinib (AST2818) is a selective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), which can irreversibly inhibit both EGFR sensitizi...

Keywords:

EGFR T790M
Cancer research
Medicine
Mutation (genetic algorithm)
Tyrosine-kinase inhibitor
Single Arm Study
Epidermal growth factor receptor
Post-hoc analysis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations